Analyst Price Targets — LINE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 13, 2026 12:19 pm | — | Barclays | $38.00 | $37.19 | TheFly | Lineage downgraded to Equal Weight from Overweight at Barclays |
| January 9, 2026 3:33 pm | — | Scotiabank | $39.00 | $36.44 | TheFly | Lineage price target raised to $39 from $37 at Scotiabank |
| January 8, 2026 11:37 am | Michael Goldsmith | UBS | $35.00 | $35.08 | TheFly | Lineage price target lowered to $35 from $41 at UBS |
| December 22, 2025 5:27 pm | — | Truist Financial | $40.00 | $34.33 | TheFly | Lineage price target lowered to $40 from $53 at Truist |
| December 18, 2025 10:16 am | Nicholas Thillman | Robert W. Baird | $39.00 | $34.80 | TheFly | Lineage downgraded to Neutral from Outperform at Baird |
| December 16, 2025 5:26 pm | — | Morgan Stanley | $39.00 | $34.25 | StreetInsider | Lineage Inc (LINE) PT Lowered to $39 at Morgan StanleyMember Login |
| November 25, 2025 7:47 pm | — | Wells Fargo | $32.00 | $35.67 | TheFly | Lineage price target lowered to $32 from $43 at Wells Fargo |
| November 25, 2025 12:05 pm | — | Goldman Sachs | $45.00 | $34.80 | TheFly | Lineage price target lowered to $45 from $50 at Goldman Sachs |
| November 6, 2025 10:13 am | — | Piper Sandler | $41.00 | $37.88 | TheFly | Lineage downgraded to Neutral from Overweight at Piper Sandler |
| November 3, 2025 11:36 am | Vikram Malhotra | Mizuho Securities | $44.00 | $39.40 | StreetInsider | Lineage Inc (LINE) PT Lowered to $44 at Mizuho |
Latest News for LINE
Lineage remains a buy, supported by strong fundamentals and a leading position in temperature-controlled warehouse REITs despite near-term macro headwinds. LINE delivered robust 2025 AFFO growth of 22.7% ($865M), but expects a ~14.7% per-share AFFO decline in 2026 amid weak occupancy and macro uncertainty. Dividend yield stands at 5.15% with a sustainable payout ratio, and management targets $110M run-rate cost…
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its fourth quarter and full year 2025 financial and operating results on Thursday, March 5, 2026, following the close of…
Centersquare Investment Management LLC lessened its position in shares of Lineage, Inc. (NASDAQ: LINE) by 44.2% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 699,550 shares of the company's stock after selling 553,625 shares during the quarter. Centersquare Investment Management LLC
Lineage, Inc. (LINE) Q4 2025 Earnings Call Transcript
Although the revenue and EPS for Lineage, Inc. (LINE) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
No House trades found for LINE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.